SPECIAL NOTICE
A -- NOTICE OF INTENT TO ENTER AGREEMENTS
- Notice Date
- 5/16/2006
- Notice Type
- Special Notice
- NAICS
- 541330
— Engineering Services
- Contracting Office
- Department of Energy, Idaho National Laboratory (DOE Contractor), Idaho National Laboratory, 2525 Fremont P.O. Box 1625, Idaho Falls, ID, 83415-3920
- ZIP Code
- 83415-3920
- Solicitation Number
- 06-09
- Response Due
- 5/30/2006
- Archive Date
- 6/14/2006
- Description
- IDAHO NATIONAL LABORATORY PROVIDES NOTICE OF INTENT TO ENTER INTO AGREEMENTS WITH A COMPANY CAPABLE OF COMMERCIALIZING METHODS FOR RECOVERY OF DAUGHTER ISOTOPES FROM A SOURCE. Announcement: Idaho National Laboratory (INL), operated by Battelle Energy Alliance, LLC (BEA) under contract with the Department of Energy (DOE) hereby gives notice of its intent to enter into agreements with a company capable of developing and implementing BEA proprietary methods for recovery of daughter isotopes from a source and delivering the recovered daughter isotopes to the medical community for clinical trials, therapeutic treatments or both. The company is NorthStar Nuclear Medicine, Inc., Janesville, Wisconsin or NNM. BEA intends to enter into an exclusive license agreement with NNM for the purpose of developing and commercializing a patented method to recover actinium 225 from INL?s excess uranium 233 for human therapeutic applications. BEA also intends to enter into a cooperative research and development agreement with NNM to plan a process for recovery of actinium 225 from INL?s excess uranium 233. If the plan is viable, the parties intend to enter into agreements to implement and operate a pilot-production facility until such time that Phase III clinical trials with bismuth 213 are completed. INL scientists have identified two distinct proprietary methods for recovery of daughter isotopes from about 14 metric tons of source material at INL. Both methods result in the recovery of actinium 225 from the source material, which includes mixed thorium isotopes containing about 40 grams of thorium 229. NNM is capable of funding pilot-plant development of one or both methods, and providing actinium 225 to the medical community for use in clinical trials, therapeutic treatments or both. Note: THIS IS NOT A PROCUREMENT. Contact information: John R. Snyder, Ph.D., Advisory Account Executive, Technology Transfer and Commercialization, BEA P.O. Box 1625, Idaho Falls, ID 83415-3805. Phone: 208-526-9812. E-mail: john.snyder@inl.gov.
- Record
- SN01048779-W 20060518/060516220324 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |